2.1 Controlled Substances Act & DEA Scheduling

The Controlled Substances Act: Federal Foundation for Every State's MPJE

Every jurisdiction's Multistate Pharmacy Jurisprudence Examination (MPJE), including New York's, sits on top of a single federal statute: the Controlled Substances Act (CSA) of 1970, codified at 21 United States Code (21 USC) §§ 801–971. Congress enacted the CSA to consolidate more than 50 separate federal drug laws into one framework and to create a closed system of distribution for substances with abuse potential — meaning every transfer of a controlled substance, from manufacturer to wholesaler to pharmacy to patient, must be traceable and authorized. The Drug Enforcement Administration (DEA), a component of the U.S. Department of Justice, implements the CSA through regulations at 21 CFR Parts 1300–1321, covering registration, security, recordkeeping, order forms, and the schedules themselves. A New York pharmacist who dispenses a controlled substance applies this federal framework first; New York's own controlled-substance statute (Public Health Law Article 33) and its implementing regulations (10 NYCRR Part 80) layer state-specific licensing and monitoring requirements on top of — never instead of — the federal CSA. That state layer is covered in a later chapter; this section focuses on the federal scheduling framework itself, which is tested in essentially identical form on every state's MPJE.

The Three Statutory Scheduling Criteria

Under 21 USC § 812(b), a substance is assigned to one of five schedules based on three statutory findings:

1. Potential for abuse — the substance's actual or relative likelihood of being used in a manner that departs from legitimate medical practice.
2. Currently accepted medical use in treatment in the United States — whether the substance has an accepted therapeutic role, as recognized by the scientific and medical community.
3. Potential for psychological or physiological dependence — the degree to which the substance can create a compulsion to continue use, or physical withdrawal symptoms on discontinuation.

These three factors interact differently across the five schedules: Schedule I substances fail the accepted-medical-use test entirely, while Schedules II through V all have accepted medical uses and are distinguished from one another primarily by the severity of abuse and dependence risk.

The Five Schedules

Refill Rules by Schedule

• Schedule I — No prescriptions of any kind; CI substances may only be handled under a DEA Schedule I researcher registration for non-clinical research, never dispensed to a patient.
• Schedule II — Dispensable by prescription, zero refills (21 CFR § 1306.12). A federal partial-fill exception allows a pharmacist to fill part of a CII quantity — because the patient cannot tolerate the full amount or the pharmacy lacks sufficient stock — and fill the remainder within 72 hours, documenting the reason on the face or reverse of the paper prescription (or electronically in the record for an EPCS prescription).
• Schedule III–V — Up to 5 refills within 6 months of the date of issue (21 CFR § 1306.22); after 5 refills or 6 months, whichever occurs first, the prescription is void and a new prescription is required.

Who Has Authority to Schedule a Substance

Scheduling authority under 21 USC § 811 formally belongs to the U.S. Attorney General, who has delegated it to the DEA Administrator. Before permanently adding, removing, or rescheduling a substance, the DEA Administrator must request a scientific and medical evaluation from the Secretary of Health and Human Services (HHS), who in turn relies on the FDA's analysis. That HHS/FDA recommendation on scientific and medical matters is binding on the DEA — the DEA cannot schedule a substance the FDA judges to have no potential for abuse. The Administrator also weighs eight statutory factors under 21 USC § 811(c), including actual/relative abuse potential, scientific evidence of the substance's pharmacological effect, the state of current scientific knowledge, and the substance's history and pattern of abuse. A permanent scheduling action generally proceeds through notice-and-comment rulemaking: a proposed rule is published in the Federal Register, the public may comment, and a final rule sets the effective schedule.

Temporary (Emergency) Scheduling

Because new synthetic drugs (novel fentanyl analogs, synthetic cannabinoids, and "bath salt" cathinones) can appear on the illicit market faster than notice-and-comment rulemaking can respond, 21 USC § 811(h) authorizes the Attorney General to temporarily place a substance into Schedule I for up to 2 years without completing the full rulemaking process, if doing so is necessary to avoid an imminent hazard to public safety. If proceedings to permanently schedule the substance are already underway when the 2-year period is set to lapse, the temporary scheduling may be extended for up to 1 additional year. This emergency authority explains why a pharmacist may see a substance move to Schedule I on comparatively short notice — DEA does not have to wait for a full rulemaking cycle when the public-safety risk is acute.

Common MPJE Traps in This Section

1. "Can a pharmacist dispense a Schedule I drug with a valid-looking prescription?" No. Schedule I has no accepted medical use; no prescription can lawfully authorize dispensing, regardless of how the prescription is written or who signs it.
2. Confusing a CII partial fill with a CIII–V refill. A CII partial fill under the 72-hour rule is not a refill; a CII prescription can never be refilled under ordinary circumstances.
3. The 90 mg codeine cutoff. Combination products with less than 90 mg of codeine per dosage unit are Schedule III (e.g., Tylenol with Codeine #3); this numeric threshold, not the drug's brand name alone, determines the schedule.
4. Assuming DEA scheduling authority is unilateral. The FDA's/HHS's scientific and medical findings are binding on DEA scheduling and rescheduling decisions — a frequently tested nuance.
5. Treating temporary scheduling as identical to permanent scheduling. Temporary scheduling under § 811(h) sunsets after 2 years (or 3 years with the extension) unless the substance is separately, permanently scheduled through full rulemaking.